This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
PROfound
VISION Trial
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
PSMA PET Imaging
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
Trials in Progress
Trials in Progress
ECLIPSE Trial
Oral EPI-7386
SPLASH Trial
Right Side
PCCTC
DORA
IRONMAN
PROMISE
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Petros Grivas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Kidney Cancer Today
Sumanta (Monty) Kumar Pal, MD
Jaime Landman, MD
Prostate Cancer
Advanced Prostate Cancer
Alicia Morgans, MD, MPH
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Alicia Morgans, MD, MPH
nmCRPC
Alicia Morgans, MD, MPH
PSMA-Targeted Therapy
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular, Penile, and Rare GU Malignancies
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Education
Covid-19
The Prostate Cancer Foundation
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Pelvic Health & Reconstruction
Endourology
Testicular Cancer
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
ASCO 2023
AUA 2023
ASCO GU 2023
EAU 2023
All Conferences
View All
PCF
UroToday Home
Recent Abstracts
Urologic Oncology
Prostate Cancer
Conferences
Recent Abstracts
ASCO 2023: Phase I/II Randomized Clinical Trial of In-Clinic Acupuncture Prior to BCG in Patients with High-Risk Non-Muscle Invasive Bladder Cancer
June 3, 2023
ASCO 2023: Survival Outcomes in Patients with Muscle-Invasive Bladder Cancer Receiving Neoadjuvant Chemotherapy Stratified by Number of Cycles
June 3, 2023
ASCO 2023: Real-World Outcomes Among Patients with Advanced/metastatic RCC Treated with Cabozantinib or Other TKIs After Checkpoint Inhibitor Therapy
June 3, 2023
ASCO 2023: EV-103: Neoadjuvant Treatment with Enfortumab Vedotin Monotherapy in Cisplatin-Ineligible Patients with MIBC: Updated Results for Cohort H
June 3, 2023
ASCO 2023: ENLIGHTED: A Phase 3 Multicenter Study to Evaluate the Safety and Efficacy of Padeliporfin Vascular Targeted Photodynamic Therapy in Treatment of Low-Grade UTUC
June 3, 2023
ASCO 2023: Age, Sex, and Race-Related Differences in Outcomes of Patients with Muscle-Invasive Bladder Cancer Treated with Radical Cystectomy: The Role of Biology Versus Access to Standard Medical Care
June 3, 2023
ASCO 2023: Testosterone Recovery Following Androgen Suppression and Prostate Radiotherapy: Updated Individual Patient Data Meta-Analyses from the MARCAP Consortium
June 3, 2023
ASCO 2023: KEYNOTE-905/EV-303: A Phase 3 Study to Evaluate the Efficacy and Safety of Perioperative Pembrolizumab or Pembrolizumab + Enfortumab Vedotin for MIBC
June 3, 2023
ASCO 2023: Basal-Luminal Subtyping of Localized High-Risk Prostate Cancer and Benefit of Adding Docetaxel to Definitive Radiotherapy with Androgen Suppression in the NRG Oncology/RTOG 0521 Phase III Trial
June 3, 2023
ASCO 2023: Post Radical Prostatectomy PSA Outcomes Following 6 vs 18 Months of Perioperative Androgen Deprivation Therapy in Men with Localized High Risk Prostate Cancer: Results of Part 2 of a Randomized Phase 2 Trial
June 3, 2023
ASCO 2023: Depth of PSA Nadir and Subsequent PSA Progression-Free Survival in Patients with High-Risk Biochemically Relapsed Prostate Cancer: Results from the Phase 3 PRESTO Study (AFT-19)
June 3, 2023
ASCO 2023: Assessing Racial Differences in Time to Treatment Escalation Following Androgen-Deprivation Therapy Among Veterans with Prostate Cancer
June 3, 2023
ASCO 2023: CABIOS Trial: A Phase Ib Study of Cabozantinib and Nivolumab in Combination with Abiraterone in Patients with Metastatic Hormone Sensitive Prostate Cancer
June 3, 2023
ASCO 2023: Darolutamide Observational (DAROL) Study in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Second Interim Analysis.
June 3, 2023
ASCO 2023: Landscape and Impact of Germline Pathogenic Variants in Metastatic Hormone Sensitive Prostate Cancer: Ancillary Study of E3805 CHAARTED
June 3, 2023
ASCO 2023: Prostate-Specific Antigen Value at 3 & 7 Months (PSA-3mo, PSA-7mo) and Overall Survival (OS) in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Treated with Androgen Deprivation (ADT) with or without Orteronel (SWOG S1216)
June 3, 2023
ASCO 2023: EV-104: A First-in-Human Trial of Intravesical Enfortumab Vedotin, an Antibody-Drug Conjugate, in Patients with NMIBC: Interim Results of a Phase 1 Study
June 3, 2023
ASCO 2023: Health-Related Quality of Life Measures in RCC: Patient-Reported Relevance of Items of the FKSI-19, EORTC QLQ-C30, and EQ-5D
June 3, 2023
ASCO 2023: Enzalutamide, Docetaxel and Androgen Deprivation (ENZADA Trial) for Metastatic Castrate Sensitive Prostate Cancer
June 3, 2023
ASCO 2023: Circulating Tumor Cells in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC) Treated with Olaparib plus 177lutetium-Prostate Specific Membrane Antigen-617 (177Lu-PSMA-617) in the LuPARP Trial
June 3, 2023
Page 4 of 520
Start
Prev
1
2
3
4
5
6
7
8
9
10
Next
End
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free